- Markets
- Healthcare
- BALPHARMA
BALPHARMA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Bal Pharma Dividend Of 1 Rupee Per Share
May 29 (Reuters) - Bal Pharma Ltd BALP.NS:
DIVIDEND OF 1 RUPEE PER SHARE
Source text for Eikon: ID:nBSE93r2ds
Further company coverage: BALP.NS
(([email protected];;))
May 29 (Reuters) - Bal Pharma Ltd BALP.NS:
DIVIDEND OF 1 RUPEE PER SHARE
Source text for Eikon: ID:nBSE93r2ds
Further company coverage: BALP.NS
(([email protected];;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Bal Pharma do?
Bal Pharma Limited is a leading Indian pharmaceutical company with over 25 years of experience. They specialize in prescription drugs, generics, intravenous infusions, and have state-of-the-art manufacturing facilities across India.
Who are the competitors of Bal Pharma?
Bal Pharma major competitors are Tyche Inds, Smruthi Organics, Mangalam Drugs&Org., Lasa Supergenerics, Everest Organics, SMS Lifesciences, Nectar Lifesciences. Market Cap of Bal Pharma is ₹174 Crs. While the median market cap of its peers are ₹156 Crs.
Is Bal Pharma financially stable compared to its competitors?
Bal Pharma seems to be less financially stable compared to its competitors. Altman Z score of Bal Pharma is 2.04 and is ranked 6 out of its 8 competitors.
Does Bal Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Bal Pharma latest dividend payout ratio is 25.66% and 3yr average dividend payout ratio is 37.69%
How has Bal Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable
How strong is Bal Pharma balance sheet?
Balance sheet of Bal Pharma is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Bal Pharma improving?
The profit is oscillating. The profit of Bal Pharma is ₹7.35 Crs for TTM, ₹7.39 Crs for Mar 2024 and ₹2.57 Crs for Mar 2023.
Is the debt of Bal Pharma increasing or decreasing?
Yes, The debt of Bal Pharma is increasing. Latest debt of Bal Pharma is ₹141 Crs as of Sep-24. This is greater than Mar-24 when it was ₹113 Crs.
Is Bal Pharma stock expensive?
Bal Pharma is not expensive. Latest PE of Bal Pharma is 23.97, while 3 year average PE is 31.11. Also latest EV/EBITDA of Bal Pharma is 10.0 while 3yr average is 10.75.
Has the share price of Bal Pharma grown faster than its competition?
Bal Pharma has given lower returns compared to its competitors. Bal Pharma has grown at ~3.17% over the last 7yrs while peers have grown at a median rate of 4.94%
Is the promoter bullish about Bal Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Bal Pharma is 50.86% and last quarter promoter holding is 50.86%.
Are mutual funds buying/selling Bal Pharma?
There is Insufficient data to gauge this.